Gibraltar Capital Management Inc. Invests $782,000 in Johnson & Johnson (NYSE:JNJ)

Gibraltar Capital Management Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,986 shares of the company’s stock, valued at approximately $782,000.

Other institutional investors also recently bought and sold shares of the company. Massachusetts Wealth Management increased its stake in shares of Johnson & Johnson by 4.2% during the 3rd quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock worth $2,508,000 after purchasing an additional 650 shares in the last quarter. Outfitter Financial LLC grew its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Outfitter Financial LLC now owns 16,857 shares of the company’s stock valued at $2,625,000 after buying an additional 105 shares during the last quarter. Signet Investment Advisory Group Inc. increased its position in Johnson & Johnson by 0.8% during the third quarter. Signet Investment Advisory Group Inc. now owns 23,365 shares of the company’s stock worth $3,639,000 after buying an additional 191 shares in the last quarter. Bfsg LLC raised its holdings in shares of Johnson & Johnson by 6.4% in the third quarter. Bfsg LLC now owns 26,069 shares of the company’s stock worth $4,060,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Avestar Capital LLC lifted its position in shares of Johnson & Johnson by 12.1% in the third quarter. Avestar Capital LLC now owns 7,094 shares of the company’s stock valued at $1,105,000 after acquiring an additional 763 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada reduced their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Trading Down 0.4 %

NYSE JNJ opened at $149.27 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 1.17. The firm has a market capitalization of $359.25 billion, a price-to-earnings ratio of 9.31, a PEG ratio of 2.46 and a beta of 0.55. The company’s 50 day moving average price is $154.19 and its 200 day moving average price is $155.03. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.32%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.